DTMT Network

Glenmark Pharmaceuticals has announced that it has launched a fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India.

While is a long-acting beta-agonist that results in bronchodilation and needed to be given once a day, Mometasone is a steroid medication used to prevent asthma attacks.

In a media statement released on June 16, 2022, the company informed that the drug, which will be marketed under the name Indamet will be available in three with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily.

Reiterating that Respiratory is a key focus area  of the company, the Group Vice President and  Head, India Formulations of  Glenmark, Alok Malik said, “We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India; offering a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.”

The launching made Glenmark the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist and Mometasone Furoate, an inhaled corticosteroid which is approved by the DCGI (Drug Controller General of India).

Data from the Global Burden of Disease report by the Institute for Health Metrics and Evaluation (IHME) reveal that proportion of mortality due to asthma in India is three times more than that of the global proportion.

The company further informed that it expects the novel fixed-dose combination will help in the management of uncontrolled asthma by improving lung function, better symptom control and reducing exacerbations.